MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Amphastar Pharmaceuticals Operating Income 2011-2026 | AMPH
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 140 M | 205 M | 197 M | 107 M | 69.9 M | 11 M | -39 K | -8.62 M | -1.27 M | 15.4 M | -6.9 M | -18 M | 17.5 M | 25.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 205 M | -18 M | 53.9 M |
Quarterly Operating Income Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.3 M | 42.2 M | 37.3 M | - | 57 M | 55.2 M | 48 M | - | 72.7 M | 36.9 M | 33.4 M | - | 23.2 M | 24.8 M | 21.6 M | - | 24.8 M | 10.6 M | 10.3 M | - | 3.52 M | -2.92 M | 7.48 M | - | 2.4 M | 973 K | -3.17 M | - | 2.55 M | -2.94 M | -9.78 M | - | -2.94 M | 2.18 M | 1.4 M | - | 5.8 M | 10.3 M | 4.08 M | - | -3.75 M | -10.3 M | -7.26 M | - | -7.82 M | -1.17 M | -1.97 M | - | 226 K | 12 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 72.7 M | -10.3 M | 13.7 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
ADMA Biologics
ADMA
|
191 M | $ 15.57 | -5.89 % | $ 3.71 B | USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.58 | -1.38 % | $ 1.07 B |  Canada |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 14.19 | -1.18 % | $ 208 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
55.4 M | $ 20.24 | 1.91 % | $ 2.55 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
584 K | $ 75.6 | -1.22 % | $ 1.46 B | USA |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.5 | -8.28 % | $ 383 M | Britain |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-49.6 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 159.87 | -2.57 % | $ 7.95 B | USA |
 |
BridgeBio Pharma
BBIO
|
-523 M | $ 65.73 | -1.22 % | $ 12.6 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-11.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
Equillium
EQ
|
-14.5 M | $ 1.79 | 2.29 % | $ 62.2 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
-24.8 M | $ 2.72 | -3.31 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
409 M | $ 60.54 | 0.18 % | $ 11.6 B | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 8.26 | -1.31 % | $ 1.36 B | Britain |
 |
Cabaletta Bio
CABA
|
-74.7 M | $ 3.2 | -6.71 % | $ 3.74 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-160 M | $ 2.93 | -8.44 % | $ 1.05 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Capricor Therapeutics
CAPR
|
-24.1 M | $ 25.74 | 0.94 % | $ 689 M | USA |